Laboratory of B-Cell Immunology

Principal Investigator: Dr. Gregg J. Silverman

Dr. Gregg J. SilvermanDr. Silverman has been involved in studies of autoimmunity since the time of his Arthritis Foundation fellowship in 1986. For more than a decade he has also directed an annual course of phage display and recombinant antibody technology at Cold Spring Harbor Labs and he is also a practicing rheumatologist with a special interest in caring for patients with lupus, rheumatoid arthritis and related conditions.

About the Laboratory of B-Cell Immunology

We are part of the Department of Medicine, and the Division of Rheumatology. Our research group has focused on the body’s capacity to produce antibodies in health and in disease, and how these antibodies coordinate the functions of the overall immune system. We have been especially interested in better understanding the disease pathways in rheumatoid arthritis and in systemic lupus erythematous. Our recent studies have led us to also investigate fundamental pathways of inflammation relevant to a broad range of diseases.  

The lab currently utilizes a broad range of technologies for our research. For the development of well-characterized monoclonal antibodies we apply protein engineering, phage- display technology, and prokaryotic expression systems. In addition, we have recently begun the production of recombinant IgG antibodies using bioreactor systems.  

To characterize in vivo antibody repertoire expression, we have developed autoantigen microarrays using a robotic printer and more recently with multiplex bead-based assays. For identifying the functional properties of antibody-based agents we have also used in vitro culture systems, to assess responses in cell lines and primary cells (see figure below). To investigate relevance to disease states, we are also exploring in vivo model inflammation systems using purified agonists for Toll-like receptors and other receptor molecules within the innate immune system, as well as murine models of inflammatory arthritis, lupus and other conditions. As our ultimate goal is to develop better therapeutic agents, we study clinical samples from patients to understand the relevance of our investigations to human immune responses.  

Since joining NYU in 2011 we have initiated studies of the effects of the gut microbiome in mice and humans on B cell responses, and we are also investigating B-cell responses during infections to Staphylococcus aureus (see research topics).